Adagene Inc. American Depositary Shares

Adagene reported 29% overall response rate for muzastotug (ADG126) in MSS colorectal cancer patients at the 20 mg/kg dose, with median overall survival of 19.4 months at 10 mg/kg dose. The company demonstrated improved tolerability with 4% discontinuation rate and no Grade 4-5 adverse events across 67 patients. With $74.5 million in cash as of De...

Adagene has signed a licensing agreement with Third Arc Bio to utilize its SAFEbody technology platform for developing two masked CD3 T cell engagers targeting unique tumor-associated antigens. The deal includes an upfront payment of $5 million and potential milestone payments up to $840 million.

Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.

Adagene will present results of ADG126, a masked anti-CTLA-4 therapy, at the Chinese Society of Clinical Oncology meeting, showcasing promising outcomes in treating microsatellite stable colorectal cancer with an objective response rate of ~30%.

Adagene received FDA feedback on its clinical development plan for muzastotug (ADG126), an anti-CTLA-4 therapy for microsatellite stable colorectal cancer, with plans to begin Phase 2 patient enrollment in 2H 2025.